11/02/2019 19:00:00

Titan Pharmaceuticals Selects Life Sciences Business Intelligence CRM Innovator, TikaMobile, to Empower its Sales and MSL Teams

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- TikaMobile, a premier cloud-based business intelligence  CRM provider for the life sciences industry, today announced that Titan Pharmaceuticals, Inc. has selected Tika’s BI/CRM platform to deliver real-time, actionable intelligence and interactive advanced analytics to its Sales and MSL teams. Titan is focused on the U.S. commercial relaunch of Probuphine® (buprenorphine) implant, its unique six-month maintenance treatment for Opioid Use Disorder (OUD).

With its unique ability to aggregate information and combine the functionality of disparate sales and marketing tools, TikaMobile will operate as Titan’s one-stop solution for its CRM and analytic needs. This will allow Titan to continue to strengthen its product launch process and leverage its Sales team to increase productivity and better drive revenue.  Titan’s MSL team will also have insights to better focus on KOLS to build stronger relationships and manage ongoing training initiatives with prescribers.

“We are pleased to be partnering with Titan as they work to change the medical landscape with their unique long-term maintenance treatment for opioid use disorder,” commented Manish Sharma, Chief Executive Officer and founder of TikaMobile. “Our advanced CRM and audience targeting capabilities will provide Titan with the intelligence and insights that their field reps need to increase their productivity, boost revenue generation and enhance the efficiency of their overall business practices.”

“Our field personnel appreciate the user-friendliness of the Tika system and the ability to view complex data in a simple and meaningful way,” said Titan’s EVP and Chief Commercial Officer, Dane Hallberg.  “We believe that Tika will provide our teams with a highly efficient way to identify opportunities, support our customers, and more-effectively manage our business in this competitive environment.”

About TikaMobile, Inc.

TikaMobile, Inc. is the premier leader in cloud-based business intelligence and CRM sales enablement software for the global life sciences industry. By combining many disparate sales and marketing tools into a single easy-to-use application, while applying prescriptive, actionable analytics across the commercial organization, Tika is transforming and optimizing sales organizations for pharmaceutical and medical device companies. Tika is committed to innovation, product excellence, and customer success and works with organizations of all sizes. Headquartered in New York City, Tika has offices in the United States, Europe and India. For more information, visit www.tikamobile.com.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine® (buprenorphine) implant, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Approved by the U.S. Food and Drug Administration in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology also has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com

Contact: Robert Thomas | TikaMobile, Inc.

(646) 650-5545 | rthomas@tikamobile.com

 

Blogo_dark_tagline.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
47
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
36
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
28
15 Apr
VELO
Solen skinner++Envarsus viser vejen med endnu engang rigtig gode data. https://www.ncbi.nlm.nih.gov..
24
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
15 Apr
VWS
Vestas i 600.. 😊 Det er en stor dag... Tillykke til de tålmodige og trofaste aktionærer.. Endelig ..
11
20 Apr
NOVO-B
En lille påskehilsen fra Alpe, med mulighed for Novo.   https://invst.ly/al3nf  
10
18 Apr
 
Hej CasHolm   da du har en alder af 12 år syntes jeg at det er vigtigt at du gøre op med dig selv om..
10
17 Apr
 
Hej 'outlook', dit opslag blev slettet fordi det ikke omhandlede markedet eller værdipapirer på noge..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sprint Corp. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2019 09:51:56
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB4 - 2019-04-21 10:51:56 - 2019-04-21 09:51:56 - 1000 - Website: OKAY